Education
About Us
Working with TipRanks
Follow Us
Neuronetics (STIM)
:STIM
STIM Stock Chart & Stats
$2.16
-$0.02(-1.30%)
At close: 4:00 PM EST
$2.16
-$0.02(-1.30%)
Day’s Range― - ―
52-Week Range$0.92 - $5.92
Previous CloseN/A
Volume92.55K
Average Volume (3M)2.07M
Market Cap
$86.98M
Enterprise Value$243.86M
Total Cash (Recent Filing)$34.65M
Total Debt (Recent Filing)$90.75M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 10, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding68,485,920
10 Day Avg. Volume2,958,378
30 Day Avg. Volume2,068,048
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.84
Price to Sales (P/S)0.68
P/FCF Ratio-1.57
Enterprise Value/Market Cap2.80
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit3.72
Enterprise Value/Ebitda-7.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.57
Revenue Forecast (FY)$149.83M
Bulls Say, Bears Say
Bulls Say
Business ModelThe company is already beginning to realize the benefits of its new model, with these types of locations seeing roughly 3x the revenue compared to the prior model.
EarningsThe company beat estimates with $38.1M in revenue, driven by $23.0M in Clinic/Greenbrook, which exceeded expectations.
Future GrowthManagement updated its FY25 guidance, raising the low-end of its revenue range, indicating confidence in future growth.
Bears Say
Cash FlowThe stock traded off on the higher-than-expected cash burn for Q1.
Core Segment PerformanceWeakness in the core Neuronetics segment was driven primarily by treatment session revenues, partly offset by system sales.
Gross MarginManagement ultimately lowered gross margin guidance as Greenbrook will be a bigger piece of overall revenue than initially expected.
Neuronetics News
STIM FAQ
What was Neuronetics’s price range in the past 12 months?
Neuronetics lowest stock price was $0.92 and its highest was $5.92 in the past 12 months.
What is Neuronetics’s market cap?
Neuronetics’s market cap is $86.98M.
When is Neuronetics’s upcoming earnings report date?
Neuronetics’s upcoming earnings report date is Mar 10, 2026 which is in 104 days.
How were Neuronetics’s earnings last quarter?
Neuronetics released its earnings results on Nov 04, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.125 by -$0.005.
Is Neuronetics overvalued?
According to Wall Street analysts Neuronetics’s price is currently Overvalued.
Does Neuronetics pay dividends?
Neuronetics does not currently pay dividends.
What is Neuronetics’s EPS estimate?
Neuronetics’s EPS estimate is -0.11.
How many shares outstanding does Neuronetics have?
Neuronetics has 68,485,920 shares outstanding.
What happened to Neuronetics’s price movement after its last earnings report?
Neuronetics reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.125. Following the earnings report the stock price went up 3.61%.
Which hedge fund is a major shareholder of Neuronetics?
Currently, no hedge funds are holding shares in STIM
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
STIM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 171.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 9.4%
Last 30 Days ▼ 9.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.50%
12-Months-Change
Fundamentals
Return on Equity
-239.53%
Trailing 12-Months
Asset Growth
96.26%
Trailing 12-Months
Company Description
Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
STIM Company Deck
STIM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong revenue growth driven by the Greenbrook clinics and improvements in cash flow management. However, the decline in NeuroStar revenue, decreased gross margins, and reduced guidance for the full year indicate challenges. Despite progress in operational efficiencies and strategic partnerships, the sentiment remains cautious due to these headwinds.View all STIM earnings summariesTechnical Analysis
Ownership Overview
12.56% Insiders
5.80% Mutual Funds
7.57% Other Institutional Investors
67.95% Public Companies and
Individual Investors